These regimens have yielded excellent long-term tumor control rates, but the corresponding clinical trials oftentimes recruited patients with WHO grade 3 gliomas or were conducted before the implementation of the IDH status as the major stratification factor for gliomas of adulthood [5, 8, 20–24]. The gene discussed is IDH2; the disease is neoplasm.